论文部分内容阅读
目的:比较替格瑞洛与氯吡格雷治疗急性冠状动脉综合征(ACS)的临床效果。方法:抽取2018年5月至2020年5月新乡市中心医院收治的ACS患者602例，按随机数字表法分为替格瑞洛组(301例)和氯吡格雷组(301例)。在基础治疗基础上，氯吡格雷组予以氯吡格雷治疗，替格瑞洛组予以替格瑞洛治疗。比较两组治疗效果，心绞痛发作次数与持续时间，不良反应发生率及治疗前后心功能包括左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)，炎性因子包括肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)，血液学指标包括血小板计数(PLT)、血小板聚集率(MPA)的变化。结果:替格瑞洛组总有效率为92.03%(277/301)，高于氯吡格雷组的70.10%(211/301)，n P<0.05；替格瑞洛组心绞痛发作次数较氯吡格雷组少，心绞痛持续时间较氯吡格雷组短(n P<0.05)；治疗后，替格瑞洛组LVESD、LVEDD较氯吡格雷组低(n P<0.05)，TNF-α、IL-6水平较氯吡格雷组低(n P<0.05)，PLT、MPA水平较氯吡格雷组低(n P<0.05)；替格瑞洛组不良反应发生率为5.98%(18/301)，低于氯吡格雷组的13.95%(42/301)，n P<0.05。n 结论:与氯吡格雷比较，替格瑞洛治疗ACS患者，可降低炎性因子水平，改善血液学情况，提高心功能，缓解临床症状，能提高疗效，且该药物用药安全性较高。“,”Objective:To compare the efficacy of ticagrelor and clopidogrel in the treatment of acute coronary syndrome (ACS).Methods:A total of 602 ACS patients treated in Xinxiang Central Hospital from May 2018 to May 2020 were selected, and divided into ticagrelor group (301 cases) and clopidogrel group (301 cases) according to random number table method. On the basis of basic treatment, clopidogrel group was given clopidogrel, and ticagrelor group was given ticagrelor. The efficacy, frequency and duration of angina attacks, incidence of adverse reactions, cardiac function including left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), inflammatory factors including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), hematological indexes including platelet count (PLT) and platelet aggregation rate (MPA) before and after treatment were compared between the two groups.Results:The total effective rate of ticagrelor group was 92.03% (277/301), which was higher than 70.10% (211/301) of clopidogrel group (n P<0.05). Compared with the clopidogrel group, the ticagrelor group had fewer angina attacks and shorter duration of angina pectoris (n P<0.05). Compared with clopidogrel group, ticagrelor group had lower LVESD, LVEDD, TNF-α, IL-6, PLT and MPA after treatment (n P<0.05). The incidence of adverse reactions in the ticagrelor group was 5.98% (18/301), which was lower than 13.95% (42/301) in the clopidogrel group (n P<0.05).n Conclusions:Compared with clopidogrel, ticagrelor in the treatment of ACS patients can reduce the level of inflammatory factors, improve hematology, improve cardiac function, alleviate clinical symptoms, improve the curative effect, with high safety.